The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•13 February 2026•

1 min read

Bristol Myers Squibb Receives Consensus 'Hold' Rating Amid Mixed Earnings

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

Bristol Myers Squibb (BMY) has received an average 'Hold' rating from 20 brokerage firms following its latest financial results. The company reported a mixed quarterly performance, where it exceeded revenue expectations but fell short of earnings per share (EPS) estimates. Despite the inconsistent earnings, analysts have set an average one-year target price of $59.20 for the stock. In a move to support shareholder value, the biopharmaceutical giant increased its quarterly dividend to $0.63 per share. This dividend hike represents a solid yield of 4.2%, providing a cushion for investors during periods of stock price volatility. The consensus rating reflects a cautious but stable outlook for the company as it navigates current market conditions.

Sources: